To B or not to B cells-mediate a healthy start to life

Clinical and Experimental Immunology

Volumn 171, Issue 2, 2013, Pages 124-134

  Nguyen, T G ^a   Ward, C M ^a   Morris, J M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Autoantibodies; Autoimmune; B cell; Pregnancy; Rituximab

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; LEUKOSIALIN; PROTEIN C; RITUXIMAB; THROMBIN; THROMBOCYTE ANTIGEN; TISSUE PLASMINOGEN ACTIVATOR;

ANTIBODY PRODUCTION; ARTICLE; AUTISM; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B CELL DEPLETION THERAPY; BURKITT LYMPHOMA; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL MATURATION; CELL SUBPOPULATION; CELL SURVIVAL; CELL THERAPY; CONGENITAL HEART BLOCK; CYTOKINE RELEASE; DISEASE EXACERBATION; DRUG SAFETY; HIGH RISK PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LACTATION; LARGE CELL LYMPHOMA; LYMPHOCYTE PROLIFERATION; MYASTHENIA GRAVIS; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMAPHERESIS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; HEART BLOCK; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; INFECTION; LYMPHOCYTE DEPLETION; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84872128734     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12001     Document Type: Article

References (118)

1. Chaouat G, Petitbarat M, Dubanchet S, Rahmati M, Ledee N. Tolerance to the foetal allograft. Am J Reprod Immunol 2010; 63:624-636.
2. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2:656-663.
3. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010; 63:601-610.
4. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008; 20:332-338.
5. DiLillo DJ, Horikawa M, Tedder TF. B-lymphocyte effector functions in health and diseases. Immunol Res 2011; 49:281-292.
6. Goldman AS. The immune system of human milk: antimicrobial, anti-inflammatory and immunomodulating properties. Pediatr Infect Dis J 1993; 12:664-671.
7. Le Clair C, Abbi T, Sandhu H, Tappia PS. Impact of maternal undernutrition on diabetes and cardiovascular disease risk in adult offspring. Can J Physiol Pharmacol 2009; 87:161-179.
8. Rinaudo PF, Lamb J. Foetal origins of perinatal morbidity and/or adult disease. Semin Reprod Med 2008; 26:436-445.
9. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun 2010; 34:J287-J299.
10. Gordon C. Pregnancy and autoimmune diseases. Best Pract Res Clin Rheumatol 2004; 18:359-379.
11. Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001; 13:195-201.
12. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 2011; 11:34-46.
13. Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006; 5:403-408.
14. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+ CD70-J Exp Med 2011; 208:67-80.
15. Nemazee D, Russell D, Arnold B etal. Clonal deletion of autospecific B lymphocytes. Immunol Rev 1991; 122:117-132.
16. Kawahara T, Ohdan H, Zhao G, Yang YG, Sykes M. Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells. J Immunol 2003; 171:5406-5414.
17. Almeida SR, Aroeira LS, Frymuller E etal. Mouse B-1 cell-derived mononuclear phagocyte, a novel cellular component of acute non-specific inflammatory exudate. Int Immunol 2001; 13:1193-1201.
18. Sun CM, Deriaud E, Leclerc C, Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 2005; 22:467-477.
19. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118:3420-3430.
20. Gustafsson E, Mattsson A, Holmdahl R, Mattsson R. Pregnancy in B-cell deficient mice: postpartum transfer of immunoglobulins prevents neonatal runting and death. Biol Reprod 1994; 51:1173-1180.
21. Mattsson R, Mattsson A, Sulila P. Allogeneic pregnancy in B-lymphocyte deprived CBA/CA mice-effects on maternal lymphoid organs and foetal survival. Dev Comp Immunol 1985; 9:709-717.
22. Vaidyanthan A, McKeever K, Anand B, Eppler S, Weinbauer GF, Beyer JC. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci 2011; 119:116-125.
23. Auyeung-Kim DJ, Devalaraja MN, Migone TS, Cai W, Chellman GJ. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol 2009; 28:443-455.
24. Medina KL, Kincade PW. Pregnancy-related steroids are potential negative regulators of B lymphopoiesis. Proc Natl Acad Sci USA 1994; 91:5382-5386.
25. Ait-Azzouzene D, Gendron MC, Houdayer M etal. Maternal B lymphocytes specific for paternal histocompatibility antigens are partially deleted during pregnancy. J Immunol 1998; 161:2677-2683.
26. Wang H, Shlomchik MJ. Maternal Ig mediates neonatal tolerance in rheumatoid factor transgenic mice but tolerance breaks down in adult mice. J Immunol 1998; 160:2263-2271.
27. Ait-Azzouzene D, Caucheteux S, Tchang F etal. Transgenic major histocompatibility complex class I antigen expressed in mouse trophoblast affects maternal immature B cells. Biol Reprod 2001; 65:337-344.
28. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters threshold for B-cell apoptosis and activation. J Clin Invest 2002; 109:1625-1633.
29. Bhat NM, Mithal A, Bieber MM, Herzenberg LA, Teng NN. Human CD5+ B lymphocytes (B-1 cells) decrease in peripheral blood during pregnancy. J Reprod Immunol 1995; 28:53-60.
30. Watanabe M, Iwatani Y, Kaneda T etal. Changes in T, B, and NK lymphocyte subsets during and after normal pregnancy. Am J Reprod Immunol 1997; 37:368-377.
31. Mahmoud F, Abul H, Omu A, Al-Rayes S, Haines D, Whaley K. Pregnancy-associated changes in peripheral blood lymphocyte subpopulation in normal Kuwaiti women. Gynecol Obstet Invest 2001; 52:232-236.
32. Medina KL, Rossi MID, Landherr K, Kincade PW. Naïve B cells in peripheral blood are reduced during normal human pregnancy. Blood 1999; 94 (Suppl. 1):54b.
33. Iwatani Y, Amino N, Tachi J etal. Changes of lymphocyte subset in normal pregnant and post-partum women: post-partum increase in NK/K (Leu 7) cells. Am J Reprod Immunol Microbiol 1988; 18:52-55.
34. Christiansen JS, Andersen AR, Osther K, Peitersen B, Bach-Mortensen N, Lebech PE. The relationship between pregnancy, HCS and B lymphocytes. Acta Pathol Microbiol Scand 1976; 84:313-318.
35. Moore MP, Carter NP, Redman CW. Lymphocyte subsets defined by monoclonal antibodies in human pregnancy. Am J Reprod Immunol 1983; 3:161-164.
36. Valdimarsson H, Mulholland C, Fridriksdottir V, Coleman DV. A longitudinal study of leucocyte blood counts and lymphocyte responses in pregnancy: a marked early increase of monocyte-lymphocyte ratio. Clin Exp Immunol 1983; 53:437-443.
37. Zimmer JP, Garza C, Butte NF, Goldman AS. Maternal blood B-cell (CD19+) percentages and serum immunoglobulin concentrations correlate with breast-feeding behaviour and serum prolactin concentration. Am J Reprod Immunol 1998; 40:57-62.
38. Glassman AB, Bennett CE, Christopher JB, Self S. Immunity during pregnancy: lymphocyte subpopulations and mitogen responsiveness. Ann Clin Lab Sci 1985; 15:357-362.
39. Birkeland SA, Kristoffersen K. Lymphocyte transformation with mitogens and antigens during normal human pregnancy: a longitudinal study. Scand J Immunol 1980; 11:321-325.
40. Vanderbeeken YE, Duchateau J, Gregoire M, Vandermeersch B, Collet H, Lucas A. Modulation of B cell stimulation of maternal serum. Immunol Invest 1991; 20:287-304.
41. Carlier Y, Rivera MT, Truyens C etal. Pregnancy and humoral immune response in mice chronically infected by Trypanosoma cruzi. Infect Immun 1987; 55:2496-2501.
42. Carbone J, Gallego A, Lanio N etal. Quantitative abnormalities of peripheral blood distinct T, B and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome. J Rheumatol 2009; 36:1217-1225.
43. Velasquillo MC, Alocer-Varela J, Alarcón-Segovia D, Cabiedes J, Sanchez-Guerrero J. Some patients with primary antiphospholipid syndrome have increased circulating CD5+ B cells that correlate with levels of IgM antiphospholipid antibodies. Clin Exp Rheumatol 1991; 9:501-505.
44. Jablonowska B, Palfi M, Matthiesen L, Selbing A, Kjellberg S, Ernerudh J. T and B lymphocyte subsets in patients with unexplained recurrent spontaneous abortion: IVIG versus placebo treatment. Am J Reprod Immunol 2002; 48:312-318.
45. Kwak JY, Beaman KD, Gilman-Sachs A, Ruiz JE, Schewitz D, Beer AE. Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Am J Reprod Immunol 1995; 34:93-99.
46. Beer AE, Kwak JY, Ruiz JE. Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles. Am J Reprod Immunol 1996; 35:376-382.
47. Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J. Immunophenotype of patients with recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2002; 103:53-57.
48. Roberts J, Jenkins C, Wilson R etal. Recurrent miscarriage is associated with increased numbers of CD5/20 positive lymphocytes and an increased incidence of thyroid antibodies. Eur J Endocrinol 1996; 134:84-86.
49. Mahmoud F, Diejomaoh M, Omu AE, Abul H, Haines D. Lymphocyte subpopulation frequency and presence of anti-cardiolipin and anti-nuclear antibodies in peripheral blood of Kuwaiti women experiencing recurrent pregnancy loss. J Obstet Gynaecol 2001; 21:587-590.
50. Tamiolakis D, Anastasiadis P, Hatzimichael A etal. Spontaneous abortions with increased CD5 positive cells in the placental tissue during the first trimester of gestation. Clin Exp Obstet Gynecol 2001; 28:261-265.
51. Matthiesen L, Berg G, Ernerudh J, Hakansson L. Lymphocyte subsets and mitogen stimulation of blood lymphocytes in preeclampsia. Am J Reprod Immunol 1999; 41:192-203.
52. Liao AH, Liu LP, Ding WP, Zhang L. Functional changes of human peripheral B-lymphocytes in preeclampsia. Am J Reprod Immunol 2009; 61:313-321.
53. Oleszczuk J, Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J. Alterations in the immune system of patients with imminent preterm labour. Gynecol Obstet Invest 2000; 49:110-113.
54. Sendag F, Itil IM, Terek MC, Yilmaz H. The changes of circulating lymphocyte sub-population in women with preterm labour: a case-controlled study. Aust NZ J Obstet Gynaecol 2002; 42:358-361.
55. Blidaru I, Zugun F, Cianga C, Carasevici E. Maternal immunophenotypic profile in normal pregnancy and preterm birth. Rev Med Chir Soc Med Nat Iasi 2002; 107:343-347.
56. Milns NR, Gardner ID. Maternal T-cells and human pregnancy outcome. J Reprod Immunol 1989; 15:175-178.
57. Bartha JL, Comino-Delgado R. Lymphocyte subpopulation in intrauterine growth retardation in women with or without pregnancies. Eur J Obstet Gynecol Reprod Biol 1999; 82:23-27.
58. Selvaggi L, Lucivero G, Iannone A etal. Analysis of mononuclear cell subsets in pregnancies with intrauterine growth retardation. Evidence of chronic B-lymphocyte activation. J Perinat Med 1983; 11:213-217.
59. Barnett MA, Rolland JM, Learmonth RP, Walters WA, Pihl E. Lymphocyte subclasses in pregnancy-induced hypertension. Aust NZ J Obstet Gynaecol 1984; 24:202-205.
60. Chen G, Wilson R, Cumming G, Walker JJ, McKillop JH. Immunological changes in pregnancy-induced hypertension. Eur J Obstet Gynecol Reprod Biol 1994; 53:21-25.
61. Rosic B, Sulovic V, Juznic N, Lazarevic B, Milacic D, Vidanovic M. The complements and immunoglobulins in different media of healthy pregnant women and in pregnant women with increased blood pressure. Clin Exp Obstet Gynecol 1990; 17:31-35.
62. Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987; 236:77-81.
63. Hardy RR, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T. Rheumatoid factor secretion from human Leu-1+ B cells. Science 1987; 236:81-83.
64. Duty JA, Szodoray P, Zheng NY etal. Functional anergy in a subpopulation of naïve B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009; 206:139-151.
65. Bohm I. Increased peripheral blood B-cells expressing the CD5 molecules in association to autoantibodies in patients with lupus erythematosus and evidence to selectively down-modulate them. Biomed Pharmacother 2004; 58:338-343.
66. Dauphinee M, Tovar Z, Talal N. B cells expressing CD5 are increased in Sjögren's syndrome. Arthritis Rheum 1988; 31:642-647.
67. Nussinovitch U, Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev 2012; 11:A377-A385.
68. Grimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B-cells. Curr Opin Rheumatol 2006; 18:456-461.
69. Saha S, Tieng A, Pepeljugoski KP, Zandamn-Goddard G, Peeva E. Prolactin, systemic lupus erythematosus, and autoreactive B-cells: lessons learnt from murine models. Clin Rev Allergy Immunol 2011; 40:8-15.
70. Pennell LM, Galligan CL, Fish EN. Sex affects immunity. J Autoimmun 2012; 38:J282-J291.
71. Panchanathan R, Shen H, Zhang X, Ho SM, Choubey D. Mutually positive regulatory feedback loop between interferons and estrogen receptor-alpha in mice: implications for sex bias in autoimmunity. PLoS ONE 2010; 5:e10868.
72. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 2004; 173:4479-4491.
73. Enghard P, Humrich JY, Chu VT etal. Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development. Eur J Immunol 2010; 40:1809-1818.
74. Li Q-Z, Zhou J, Lian Y etal. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol 2010; 159:281-291.
75. Mehdi AA, Uthman I, Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunity in the future. Eur J Clin Invest 2010; 40:451-464.
76. Salomonsson S, Strandberg L. Autoantibodies associated with congenital heart block. Scand J Immunol 2010; 72:185-188.
77. Buyon JP, Winchester RJ, Slade SG etal. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36:1263-1273.
78. Neri F, Chimini L, Bonomi F etal. Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus 2004; 13:805-811.
79. Vinet E, Pineau CA, Bernatsky S, Gordon C, Clarke AE. Long term outcome of children born to mothers with SLE. Arthritis Rheum 2008; 57 (Suppl. 1):S804.
80. Delpy L, Douin-Echinard V, Garidou I, Bruand C, Saoudi A, Guery JC. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J Immunol 2005; 175:5050-5057.
81. Vincent A, Jacobson L, Plested P etal. Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita. Ann NY Acad Sci 1998; 841:482-496.
82. Steinborn A, Seidl C, Sayehli C etal. Anti-fetal immune response mechanisms may be involved in the pathogenesis of placental abruption. Clin Immunol 2004; 110:45-54.
83. Herse F, Verlohren S, Wenzel K etal. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 2009; 53:393-398.
84. Zhou CC, Zhang Y, Irani RA etal. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14:855-862.
85. Lulla RR, Allen GA, Zakarija A, Green D. Transplacental transfer of postpartum inhibitors to factor VIII. Haemophilia 2010; 6:14-17.
86. Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW. Antibodies against fetal brain in sera of mother with autistic children. J Neuroimmunol 2008; 194:165-172.
87. Braunschweig D, Ashwood P, Krakowiak P etal. Autism: maternally derived antibodies specific for fetal brain protein. Neurotoxicology 2008; 29:226-231.
88. Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioural alteration: a pregnant dam mouse model. J Neuroimmunol 2009; 211:45-48.
89. Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun 2008; 22:806-816.
90. Lemke H, Tanasa RI, Trad A, Lange H. Benefits and burden of the maternally-mediated immunological imprinting. Autoimmun Rev 2009; 8:394-399.
91. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 2001; 345:1331-1335.
92. Fewtrell M, Wilson DC, Lucas A. When to wean? How good is the evidence for six months' exclusive breastfeeding. BMJ 2011; 342:209-212.
93. Greeley SA, Katsumata M, Yu L etal. Elimination of maternally transmitted autoantibodies prevents diabetes in non-obese diabetic mice. Nat Med 2002; 8:399-402.
94. Koczwara K, Bonifacio E, Zeigler AG. Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes 2004; 53:1-4.
95. Gill TJ III, Repetti CF, Metlay LA etal. Transplacental immunization of the human fetus to tetanus by immunization of the mother. J Clin Invest 1983; 72:987-996.
96. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 2007; 25:6296-6304.
97. Ng CT, Jaworski JP, Jayaraman P etal. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010; 16:1117-1119.
98. Puleston RL, Bugg G, Hoschler K etal. Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy. Health Technol Assess 2010; 14:1-82.
99. Glezen WP. Effect of maternal antibodies on the infant immune response. Vaccine 2003; 21:3389-3392.
100. Van de Perre P, Simonon A, Hitimana DG etal. Infective and anti-infective properties of breast milk from HIV-1-infected women. Lancet 1993; 341:914-918.
101. Leandro MJ, de la Torre I. Translational mini-review series on B cell-directed therapies: the pathogenic role of B-cells in autoantibody-directed autoimmune diseases-lessons from B cell-depletion therapy. Clin Exp Immunol 2009; 157:191-197.
102. Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001; 19:3439.
103. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004; 72:292-295.
104. Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006; 26:252-255.
105. Decker M, Rothermundt C, Hollander G, Tichelli A, Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 2006; 7:693-694.
106. Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006; 91:1426-1427.
107. Scully M, Starke R, Lee R, Mackie I, Machin S, Cohen H. Successful management of pregnancy in women with a history of thrombotic thrombocytopenia purpura. Blood Coagul Fibrinolysis 2006; 17:459-463.
108. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008; doi: 10.1155/2008/271363.
109. Rey J, Coso D, Roger V etal. Rituximab combined with chemotherapy for lymphoma during pregnancy. Leuk Res 2009; 33:e8-9.
110. Gall B, Yee A, Berry B etal. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J Obstet Gynaecol Can 2010; 32:1167-1171.
111. Ponte P, Paiva MJ. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol 2010; 63:355-356.
112. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011; 117:1499-1506.
113. ® [package insert]. Genentech and Biogen Idec Inc., South San Francisco, CA and Cambridge, MA.
114. Carson K, Focosi D, Major EO etal. Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10:814-824.
115. van Oers MH, Van Glabbeke M, Giurgea L etal. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853-2858.
116. Nguyen TG, Little CB, Yenson VM etal. Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance. J Autoimmun 2010; 35:86-97.
117. Stohl W, Scholz JL, Cancro MP. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol 2011; 23:305-310.
118. Vossenkamper A, Lutalo MPK, Spencer J. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol 2012; 167:7-14.